NVCTNuvectis Pharma, Inc.
$20.13+229% 1Y
$20.13
$5.6552 weeks$28.52
NVCT in its own filings
Nothing in NVCT's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
79
Events found in the filings · across 273 filings · the record starts in 2021
- Hard flags
- none
Hard flags
- Most recent filing
- Aug 21, 2026
Most recent filing · Form 8-K
- Record starts
- Aug 26, 2021
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 3, 2026
- SEC comment-letter activity17 occurrences
- 2026-02-18
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 21, 2026Establishment of “At the Market” Offering Program On August 21, 2026, Nuvectis Pharma, Inc., a Delaware corporation (the “Company”), entered into an Open Market Sale Agreement SM (the “Sale Agreement”) with Jefferies LLC (“Jefferies”) as sales agent, pursuant to which the Company may offer and sell shares (the “ATM …Other event · Form 8-K
- Aug 4, 2026Nuvectis Pharma Reports Second Quarter.Earnings release · press release
- Jun 30, 2026On June 29, 2026, Nuvectis Pharma, Inc. (“Nuvectis” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co. (the “Representative”)Material agreement entered · Form 8-K
- Jun 29, 2026As previously disclosed, on May 9, 2025, Nuvectis Pharma, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC (the “Agent”) pursuant to which the Company may sell, from time to time, at its option, shares (the “Shares”) of the Company’s common stock (the “Common …Other event · Form 8-K
- Jun 23, 2026Haisco License Agreement On June 22, 2026, Nuvectis Pharma, Inc., a Delaware corporation (the “Company”), entered into a license agreement (the “License Agreement”) with Haisco Pharmaceutical Group Co., Ltd. (“Haisco”)Material agreement entered · Form 8-K
- May 5, 2026Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results.Earnings release · press release
- Feb 11, 2026Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business.Earnings release · press release
- Nov 4, 2025Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results.Earnings release · press release
- Sep 25, 2025On September 22, 2025, the Board of Directors (the “Board”) of Nuvectis Pharma, Inc. (the “Company”) appointed Juan Sanchez, MD, to the Board.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…